Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright analyst Patrick Trucchio maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 28.9% a
A Quick Look at Today's Ratings for Immunocore(IMCR.US), With a Forecast Between $81 to $92
On Jun 04, major Wall Street analysts update their ratings for $Immunocore(IMCR.US)$, with price targets ranging from $81 to $92.Goldman Sachs analyst Rajan Sharma maintains with a buy rating.Barclays
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Express News | Immunocore : Guggenheim Cuts Target Price to $76 From $92
Buy Rating on Immunocore Holdings Backed by Promising Phase I/II Study Results and Potential T-cell Profile Benefits
Buy Rating Affirmed: Immunocore's Promising Survival Data and High Disease Control Rate in Advanced Melanoma
Immunocore Says New Data Demonstrates Kimmtrak Efficacy for Uveal Melanoma
Express News | Immunocore Presents Kimmtrak Clinical Data Demonstrating That Patients With Stable Disease and Confirmed Tumor Reduction Have Similar Clinical Outcomes to Patients With Partial Response
Immunocore Presents KIMMTRAK Clinical Data Demonstrating That Patients With Stable Disease and Confirmed Tumor Reduction Have Similar Clinical Outcomes to Patients With Partial Response
Immunocore Holdings plc (Nasdaq: IMCR) today presented three posters about KIMMTRAK (tebentafusp-tebn) for the treatment of patients with unresectable or metastatic uveal melanoma (mUM) at the 2024 ASCO (American Society for Clinical Oncology) Annual Meeting.
Express News | Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Express News | Immunocore - Monotherapy Brenetafusp in Late-Line Cutaneous Melanoma Demonstrated Promising Progression Free Survival and Ctdna Molecular Response
Express News | Immunocore - Monotherapy Brenetafusp in Late-Line Cutaneous Melanoma Demonstrated Promising Disease Control (Partial Response and Stable Disease)
Express News | Immunocore : Clinical Activity Was Enriched in Prame Positive Patients With 58% Disease Control Rate and 4.2 Months Median Pfs
Express News | Immunocore : Peripheral Blood T Cell Fitness Was Associated With Increased Brenetafusp Clinical Activity and Was Higher in Earlier Lines of Therapy
Express News | Immunocore : Brenetafusp Is Well Tolerated as Monotherapy and in Combination With Anti-Pd1
Express News | Immunocore Reports Updated Phase 1 Data of Brenetafusp (Imc-F106C), an Immtac Bispecific Targeting Prame, in Immune Checkpoint Pre-Treated Cutaneous Melanoma Patients at Asco 2024
Express News | HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $100 Price Target
Positive Outlook for Immunocore's KIMMTRAK Bolsters Buy Rating Amidst Advancing Clinical Trials
Express News | Following Consultation With FDA, Immunocore Converts The TEBE-AM Phase 2/3 Clinical Trial Into A Phase 3 Trial For Kimmtrak For Previously Treated Advanced Cutaneous Melanoma
No Data